Ex­clu­sive: As­traZeneca signs off on a ‘car­bon neg­a­tive’ new biotech build­ing for one of its lat­est buy­outs

Break­through Prop­er­ties is back keep­ing the dirt fly­ing in biotech — this time break­ing new ground in Am­s­ter­dam.

The com­mer­cial re­al es­tate al­liance be­tween Tish­man Spey­er …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN